Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-03-10, Stock:NVS, The news for the past five days is as follows:
2021-03-03: nan
2021-03-04: NEWS1: U.S. COVID death toll above 518,000 as Biden adds voice to outrage at Texas and Mississippi for reopening.NEWS2: Novartis Will Help Manufacture CureVac’s Covid-19 Vaccine.NEWS3: Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer.NEWS4: Novartis Lends Support To Manufacture CureVac's COVID-19 Shots.NEWS5: UPDATE 2-Novartis joins CureVac's vaccine contractor line-up.NEWS6: Novartis agrees to help make CureVac COVID-19 vaccine.
2021-03-05: NEWS1: Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine.NEWS2: Novartis announces change to the Executive Committee.
2021-03-08: nan
2021-03-09: NEWS1: Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint.NEWS2: Novartis' Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial.NEWS3: The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data.NEWS4: Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study.NEWS5: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer.

Answer: Rise